DEFA14A: ATAI to Acquire Beckley Psytech, BPL-003 Shows Strong Phase 2b Results

ATAI Life Sciences N.V. announced its definitive agreement to acquire Beckley Psytech Limited, following positive Phase 2b clinical trial results for BPL-003 and a $50 million PIPE financing.

Summary

• ATAI Life Sciences N.V. (atai) has entered into a Share Purchase Agreement (SPA) to acquire the remaining issued share capital of Beckley Psytech Limited (Beckley Psytech) not already owned by atai, which currently stands at 33.7%.
• The acquisition is expected to close in the fourth quarter of 2025, subject to atai shareholder approval and other customary closing conditions.
• Prior to closing, Beckley Psytech will spin off Eleusis and its subsidiaries (Beckley Carve-Out) to its existing shareholders, who will receive a pro-rata equity holding in Eleusis.
• atai completed a July PIPE Financing, raising approximately $50.0 million through the issuance of 18,264,840 Ordinary Shares and pre-funded warrants to purchase 4,566,210 Ordinary Shares.
• atai advanced up to $10.0 million to Beckley Psytech via a senior promissory note on August 13, 2025, to fund BPL-003 development milestones.
• Beckley Psytech reported a loss for the year of (£22.469 million) in 2024, an increase from (£6.002 million) in 2023, and an operating loss of (£35.923 million) in 2024.
• Beckley Psytech is not currently generating revenue and has incurred net losses and cash outflows from operating activities since inception, with a material uncertainty regarding its ability to continue as a going concern without additional financing.
• On July 1, 2025, Beckley Psytech announced positive topline results from its BPL-003-201 Phase 2b study, which met its primary and all key secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects with a single dose.
• The preliminary estimated purchase consideration for the acquisition is approximately $523.2 million, with an estimated fair value of acquired In-Process Research & Development (IPR&D) of $536.0 million.
• atai expects to complete a Redomiciliation from a Dutch public company to a Luxembourg entity, then to a Delaware corporation, before the end of 2025.

Sentiment

Score: 8

Explanation: The positive Phase 2b clinical trial results for BPL-003 are a significant de-risking event and a strong positive catalyst. The acquisition by atai provides a crucial financial lifeline and a larger platform for the asset's development, mitigating Beckley Psytech's standalone going concern issues. While the inherent risks of clinical development and M&A integration remain, the promising clinical data and strategic alignment create a favorable outlook.

Positives

• Positive topline results for BPL-003-201 Phase 2b study, meeting primary and all key secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects with a single dose.
• The acquisition by atai provides a clear path for Beckley Psytech's BPL-003 program to continue development, addressing Beckley Psytech's standalone going concern risks.
• atai successfully completed a July PIPE Financing, raising $50.0 million, strengthening its capital position.
• atai provided a $10.0 million promissory note to Beckley Psytech, ensuring interim funding for BPL-003 development milestones.

Negatives

• Beckley Psytech is not currently generating revenue and has incurred significant net losses and net cash outflows from operating activities since its inception.
• Beckley Psytech's operating loss increased to (£35.923 million) in 2024 from (£14.546 million) in 2023.
• Beckley Psytech's loss for the year increased to (£22.469 million) in 2024 from (£6.002 million) in 2023.
• A material uncertainty exists regarding Beckley Psytech's ability to continue as a going concern without additional financing, despite the expected acquisition.
• The pro forma combined financial information for atai shows substantial net losses, with a pro forma net loss per share of $(0.28) for the six months ended June 30, 2025, and $(2.55) for the year ended December 31, 2024.

Risks

• The proposed acquisition may not be completed in a timely manner or at all, including the risk that required shareholder approvals are not obtained.
• There is a risk of failure to realize the anticipated benefits of the proposed transactions.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the Share Purchase Agreement.
• The announcement or pendency of the proposed transactions could affect atai's ability to retain and hire key personnel, or its operating results and business generally.
• Beckley Psytech's ability to continue as a going concern is uncertain if the acquisition does not close or if additional funding is not secured in time.
• Delays in the receipt of R&D tax credits could impact Beckley Psytech's financial condition and ability to pursue business strategies.
• The final purchase price for the acquisition could significantly differ from preliminary estimates due to fluctuations in atai's Ordinary Shares price up to the closing date.
• Shareholders voting against the Redomiciliation may exercise withdrawal rights, potentially leading to up to $5.0 million in cash compensation.

Future Outlook

The acquisition of Beckley Psytech by atai is expected to close in the fourth quarter of 2025, subject to shareholder approval. atai also plans to complete its Redomiciliation before the end of 2025. Beckley Psytech anticipates continued net losses and cash outflows in the short to medium term, but the acquisition and promissory note from atai are expected to provide necessary funding for ongoing operations and BPL-003 development. The positive Phase 2b results for BPL-003 suggest continued progress towards commercialization.

Management Comments

• Management has prepared a cash flow forecast for the Group and has considered the ability for the Group to continue as a going concern for the foreseeable future, being at least 12 months after approving these financial statements.
• The directors forecast that without additional financing, current existing resources will not be sufficient to fund its ongoing operations for at least 12 months after approving these financial statements.
• The board of atai has previously approved the Acquisition, and the directors consider it likely that the Acquisition will close within the going concern period and have visibility to the plans, strategy and funding of the Group under atais prospective ownership.
• Managements cash flow forecast for the Group taking account of the Promissory Note from atai together with R&D tax credits expected to be received under the normal operations of the business, extend the Groups cash runway for at least 12 months beyond the date these consolidated financial statements are available to be issued.
• However, there is no guarantee that the Acquisition will close and that atai will provide adequate cash inflows to the Group following the closing of the transaction, nor that other additional funding or the R&D tax credits will be received in time to enact the business plan.
• Though management believes its judgments, assumptions and estimates are appropriate, actual results may differ from such estimates under different assumptions, macroeconomic and market conditions.

Industry Context

This acquisition positions atai to strengthen its pipeline in the burgeoning psychedelic medicine sector, a field gaining increasing attention for its potential in treating mental health disorders. The positive Phase 2b results for BPL-003, a novel antidepressant, are a significant development in this space, indicating potential for a new therapeutic option. The strategic move by atai to acquire a clinical-stage company with promising assets is consistent with trends in the biotechnology and pharmaceutical industries where larger entities seek to expand their portfolios through M&A.

Comparison to Industry Standards

• The acquisition of clinical-stage biotechnology companies by larger pharmaceutical or biotech firms is a common industry strategy to expand pipelines and leverage development expertise.
• The UK's R&D tax credit regime, which provides cash rebates for qualifying research and development expenditure, is a standard government incentive supporting innovation in the life sciences sector, comparable to similar incentives in other developed nations.
• While specific comparable companies or projects are not detailed in the filing, the positive Phase 2b results for BPL-003 suggest a competitive profile within the antidepressant development landscape, particularly given the rapid and durable effects reported, which could differentiate it from existing treatments.

Management Changes

Corporate Governance

Related Party Transactions

• atai Life Sciences N.V. (current 33.7% shareholder) is acquiring the remaining shares of Beckley Psytech Limited.
• atai provided a senior promissory note of up to $10.0 million to Beckley Psytech on August 13, 2025.
• atai made an initial investment in Beckley Psytech on January 3, 2024, acquiring 24,096,385 Series C shares and warrants, and depositing $15.0 million into an escrow account.
• A secondary share sale occurred on January 18, 2024, where atai acquired 11,153,246 ordinary shares of Beckley Psytech from existing shareholders for $10.0 million.
• Payments of £0.03 million were made to the Beckley Foundation (an associated charity) in 2024 and 2023 for a payment license.
• Beckley Psytech has committed to paying a royalty of 1% of net revenues to the Beckley Foundation, expected once the company becomes revenue-generating.

Stakeholder Impact

• **Shareholders (atai):** Potential for significant value creation from the promising BPL-003 asset, but also dilution from new share issuance for the acquisition and PIPE financing. Will vote on key corporate actions including the acquisition and redomiciliation.
• **Shareholders (Beckley Psytech):** Will receive atai Ordinary Shares as consideration for their holdings, providing liquidity and integration into a larger, publicly traded entity. Will also receive a pro-rata equity holding in Eleusis through the carve-out.
• **Employees (Beckley Psytech):** Share options will be replaced with atai awards or consideration shares, providing continued equity incentives. The repricing of underwater options aims to retain and motivate staff.
• **Customers/Patients:** The positive Phase 2b results for BPL-003 offer hope for a new, effective treatment for depression, potentially benefiting a significant patient population.
• **Creditors (Beckley Psytech):** The acquisition by atai and the provision of a promissory note significantly de-risk Beckley Psytech's going concern issues, improving its financial stability and ability to meet obligations.
• **Regulatory Authorities:** The Redomiciliation and acquisition will involve regulatory oversight and approvals in multiple jurisdictions.

Next Steps

• atai shareholders will vote on the acquisition, director nominees, and a name change to Atai Beckley N.V. at a General Meeting in the second half of 2025.
• The Beckley Carve-Out, spinning off Eleusis and its subsidiaries to existing Beckley Psytech shareholders, is expected to be completed prior to the acquisition closing.
• atai's Redomiciliation to a Delaware corporation is expected to be completed before the end of 2025.
• Further development milestones for BPL-003 will be pursued under atai's ownership.
• The financial impact of the acquisition will be evaluated and disclosed in subsequent financial statements of Beckley Psytech Limited.

Key Dates

Recommendation

The positive Phase 2b clinical trial results for BPL-003, demonstrating rapid, robust, and durable antidepressant effects, represent a significant de-risking event and a strong indicator of future commercial potential. The acquisition by atai provides a crucial strategic and financial foundation for BPL-003's continued development and eventual market entry, effectively addressing Beckley Psytech's standalone going concern challenges. While integration risks and the inherent uncertainties of late-stage clinical development exist, the promising clinical data, combined with atai's capital raise and strategic commitment, suggest a compelling long-term investment opportunity in the psychedelic medicine space.

Keywords

atai, Beckley Psytech, acquisition, merger, BPL-003, psychedelic medicine, clinical trials, Phase 2b, mental health, IPR&D, biotechnology, pharmaceutical, corporate action, SEC filing, Form 8-K, DEFA14A, PIPE financing, Redomiciliation